Form 4: Edwards Lifesciences CFO Trades Shares

Edwards Lifesciences CFO Scott B. Ullem reports transactions involving common stock, including purchases and sales executed under a Rule 10b5-1 trading plan.

Summary

• Scott B. Ullem, Chief Financial Officer of Edwards Lifesciences Corp., has reported transactions related to the company's common stock.
• These transactions include the acquisition of 13,000 shares at a price of $59.2567 and the disposition of 4,676 shares at a weighted average price of $80.4963, and 8,324 shares at a weighted average price of $79.7866.
• The acquisition of 13,000 shares was made under a Rule 10b5-1 trading plan adopted on July 29, 2025.
• Following these transactions, Ullem beneficially owns 52,699 shares directly and 266,318 shares indirectly through a trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While there are both acquisitions and dispositions, the transactions were conducted under a pre-established Rule 10b5-1 plan, indicating a structured approach rather than a reaction to new information.

Positives

• The acquisition of 13,000 shares at $59.2567 suggests a belief in the stock's value at that price point.
• The existence of a Rule 10b5-1 trading plan indicates pre-planned, systematic trading activity, which can be viewed positively as it mitigates insider trading concerns.

Negatives

• The sale of a significant number of shares (4,676 and 8,324) at prices higher than the acquisition price ($80.4963 and $79.7866 compared to $59.2567) indicates the CFO is realizing gains on previously acquired stock.
• The weighted average sale prices are higher than the acquisition price, suggesting a profitable exit for a portion of the holdings.

Risks

• The sale of shares by a key executive could be interpreted by the market as a lack of confidence in future price appreciation, although it was executed under a pre-arranged plan.
• The specific details of the Rule 10b5-1 plan, including the rationale for the specific buy and sell orders, are not fully disclosed in this filing.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The transactions are historical events reported after they occurred, though the Rule 10b5-1 plan implies future transactions may occur under its terms.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025.
• This transaction was executed in multiple trades at prices ranging from $80.225 to $80.750. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
• This transaction was executed in multiple trades at prices ranging from $79.210 to $80.200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
• This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

Industry Context

StockSavvy.ai notes that Form 4 filings by C-suite executives are common and provide transparency into insider trading activity. The use of Rule 10b5-1 plans is a standard practice for executives to diversify holdings or manage personal finances while adhering to insider trading regulations.

Stakeholder Impact

• Shareholders: The transactions provide insight into the financial activities of a key executive, which may influence investor sentiment, though the Rule 10b5-1 plan aims to mitigate this.
• Employees: The transactions do not directly impact employees but reflect the financial management of company leadership.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The reporting person may continue to execute trades under the existing Rule 10b5-1 trading plan.
• The company may provide further information regarding the transactions upon request from regulatory bodies or security holders.

Key Dates

Keywords

Form 4, SEC Filing, Edwards Lifesciences, EW, Scott B. Ullem, CFO, Insider Trading, Rule 10b5-1, Stock Transaction, Beneficial Ownership, Common Stock